Acute and repeated administration of fluoxetine, citalopram, and paroxetine significantly alters the activity of midbrain dopamine neurons in rats: An in vivo electrophysiological study

Synapse

Volumn 61, Issue 2, 2007, Pages 72-77

  Sekine, Yoshimoto ^a   Suzuki, Katsuaki ^a   Ramachandran, P Veeraraghavan ^b   Blackburn, Thomas P ^c   Ashby Jr , Charles R ^d,e  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b PURDUE UNIVERSITY   (United States)

^c Helicon Therapeutics Inc   (United States)

^d Street John's University ^*  (United States)

^e ST JOHN'S UNIVERSITY   (United States)

Author keywords

DA neurons; In vivo electrophysiology; Serotonin reuptake inhibitors

Indexed keywords

CITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; ELECTROPHYSIOLOGY; IN VIVO STUDY; MALE; MESENCEPHALON; NEUROPHYSIOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SUBSTANTIA NIGRA; TREATMENT DURATION; VENTRAL TEGMENTUM;

ACTION POTENTIALS; ANALYSIS OF VARIANCE; ANIMALS; CITALOPRAM; DOPAMINE; DRUG ADMINISTRATION SCHEDULE; FLUOXETINE; MALE; MESENCEPHALON; NEURONS; PAROXETINE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN UPTAKE INHIBITORS;

EID: 33845529951     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20349     Document Type: Article

References (58)

1. 2 receptor expression and dopamine release in the nucleus accumbens of the rat. Psychopharmacology 140:470-477.
2. Barnes NM, Sharp T. 1999. A review of central 5-HT receptors and their function. Neuropharmacology 38:1082-1152.
3. Beyer C, Boikess S, Luo B, Dawson LA. 2002. Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: An in-vivo microdialysis study. J Psychopharmacol 16:297-304.
4. Bonhomme N, Esposito E. 1998. Involvement of serotonin and dopamine in the mechanism of action of novel antidepressants. J Clin Psychopharmacol 18:447-454.
5. Bymaster FP, Zhang W, Carter PA, Shaw J, Chernet E, Phebus L, Wong DT, Perry KW. 2002. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular level in prefrontal cortex. Psychopharmacology 160:353-361.
6. Chiodo LA, Bunney BS. 1983. Typical and atypical neuroleptics- Differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 3:1607-1619.
7. Clark RN, Ashby CR Jr, Dewey SL, Ramachandran PV, Strecker RE. 1996. Effect of acute and chronic fluoxetine on extracellular dopamine levels in the caudate-putamen and nucleus accumbens of rat. Synapse 23:125-131.
8. Collu M, Poggiu AS, Serra G. 1996. Antidepressants sensitize the dopamine mesolimbic reward system mediating reward. Behav Pharmacol 7 (Suppl 1):18,19.
9. 2 receptors in chronic fluoxetine-treated rats. Eur J Pharmacol 322:123-127.
10. Cryan JF, O'Leary OF, Jin SH, Friedland JC, Ouyang M, Hirsch BR, Page ME, Dalvi A, Thomas SA, Lucki I. 2004. Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proc Natl Acad Sci USA 101:8186-8191.
11. D'Aquila PS, Monleon S, Borsini F, Brain P, Willner P. 1997. Antianhedonic actions of the novel serotonergic agent fibanserin, a potential rapidly-acting antidepressant. Eur J Pharmacol 340:121-132.
12. D'Aquila PS, Collu M, Gessa GL, Serra G. 2000. The role of dopamine in the mechanism of action of antidepressants. Eur J Pharmacol 405:365-373.
13. David DJ, Bourin M, Jego G, Przybylski C, Jolliet P, Gardier AM. 2003. Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: A microdialysis study in Swiss mice. Br J Pharmacol 140:1128-1136.
14. Dewey SL, Smith GS, Logan J, Alexoff D, Ding YS, King P, Pappas N, Brodie JD, Ashby CR Jr. 1995. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci 15:821-829.
15. Di Mascio M, Esposito E. 1997. The degree of inhibition of dopaminergic neurons in the ventral tegmental area induced by selective serotonin reuptake inhibitors is a function of the density-power-spectrum of the interspike interval. Neuroscience 79:957-961.
16. Di Mascio M, Di Giovanni G, Di Matteo V, Frisco S, Esposito E. 1998. Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area. Brain Res Bull 46:547-554.
17. Dziedzicka-Wasylewska M, Willner P, Papp M. 1997. Changes in dopamine receptor mRNA expression following chronic mild stress and chronic antidepressant treatment. Behav Pharmacol 8:607-618.
18. 3H]-5-hydroxytryptamine. Br J Pharmacol 88:677-684.
19. Hajos-Korcsok E, McTavish SF, Sharp T. 2000. Effect of a selective 5-hydroxytryptamine reuptake inhibitor on brain extracellular noradrenaline: Microdialysis studies using paroxetine. Eur J Pharmacol 407:101-107.
20. Henry DJ, Greene MA, White FJ. 1989. Electrophysiological effects of cocaine in the mesoaccumbens dopamine system: Repeated administration. J Pharmacol Exp Ther 251:833-839.
21. Hyttel J. 1994. Pharmacological characterization of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 9 (Suppl 1):19-26.
22. Ichikawa J, Meltzer HY. 1995. Effects of antidepressants on striatal and accumbens extracellular dopamine levels. Eur J Pharmacol 281:255-261.
23. Ichikawa J, Kuroki T, Meltzer HY. 1998. Differential effects of chronic imipramine and fluoxetine on basal and amphetamine-induced extracellular dopamine levels in rat nucleus accumbens. Eur J Pharmacol 350:159-164.
24. 1C receptors and antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 18:563-574.
25. Jordan S, Kramer GL, Zukas PK, Moeller M, Petty F. 1994. In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine and fluvoxamine. Synapse 18:294-297.
26. 123I]IBZM single photon emission computed tomography (SPECT). Psychiatry Res 90:91-101.
27. Kugaya A, Seneca NM, Snyder PJ, Williams SA, Mailson RT, Baldwin RM, Seibyl JP, Innis RB. 2003. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology 28:413-420.
28. 3 receptor gene expression as a common effect of chronic antidepressants. Mol Psychiatry 5:378-388.
29. Leonard BE. 1996. The comprehensive pharmacological properties of selective serotonin re-uptake inhibitors in animals. In: Feighner JP, Boyer EF, editors. Selective serotonin re-uptake inhibitors: Advances in basic research and clinical practice, 2nd ed. New York: Wiley. pp 35-62.
30. Lucki I, O'Leary OF. 2004. Distinguishing roles for norepinephrine and serotonin in the behavioral effects of antidepressant drugs. J Clin Psychiatry 65 (Suppl 4):411-424.
31. Maj J, Rogoz Z, Skuza G, Sowinska H. 1989. Antidepressants given repeatedly increase the behavioural effect of dopamine D-2 agonists. J Neural Transm Gen Sect 78:1-8.
32. 3 receptor in the rat brain. Eur J Pharmacol 351:31-37.
33. 2C receptors are involved in the discriminative stimulus effects of citalopram in rats. Psychopharmacology 142:432-434.
34. Millan MJ, Gobert A, Lejeune F, Newman-Tancredi A, Rivet JM, Auclair A, Peglion JL. 2001. S33005, a novel ligand at both serotonin and norepinephrine transporters. I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther 298:565-580.
35. Nakayama K. 2001. Effect of paroxetine on extracellular serotonin and dopamine levels in the prefrontal cortex. Naunyn Schmiedebergs Arch Pharmacol 365:102-105.
36. Nemeroff CB, Owens MJ. 2003. Neuropharmacology of paroxetine. Psychopharmacol Bull 37 (Suppl 1):8-18.
37. Owens MJ, Knight DL, Nemeroff CB. 2001. Second-generation SSRIs: Human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50:345-350.
38. Paxinos G, Watson C. 1986. The rat brain in stereotaxic coordinates. New York: Academic Press.
39. 11C]raclopride. Int J Neuropsychopharmacol 7:431-439.
40. Perry KW, Fuller RW. 1992. Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum. Life Sci 50:1683-1690.
41. Pogarell O, Poepperl G, Mulert C, Hamann C, Sadowsky N, Riedel M, Moeller HJ, Hegerl U, Tatsch K. 2005. SERT and DAT availabilities under citalopram treatment in obsessive-compulsive disorder (OCD). Eur Neuropsychopharmacol 15:521-524.
42. Prisco S, Esposito E. 1995. Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurons in the ventral tegmental area. Br J Pharmacol 116:1923-1931.
43. Renard CE, Fiocco AJ, Clenet F, Hascoey M, Bourin M. 2001. Is dopamine implicated in the antidepressant-like effects of selective serotonin reuptake inhibitors in the mouse forced swim test? Psychopharmacology 159:142-150.
44. Saland LC, Wallace JA, Coumas F. 1986. Serotonin-immunoreactive nerve fibers of the rat pituitary: Effects of anticatecholamine and antiserotonin drugs on staining patterns. Brain Res 368:310-318.
45. Sanchez C, Bergqvist PB, Brennum LT, Gupta S, Hogg S, Laresen A, Wiborg O. 2003a. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology 167:353-362.
46. Sanchez C, Gruca P, Papp M. 2003b. R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav Pharmacol 14:465-470.
47. Serra G, Collu M, D'Aquila PS, Gessa GL. 1992. Role of the mesolimbic dopamine system in the mechanism of action of antidepressants. Pharmacol Toxicol 71 (Suppl 1):72-85.
48. Soubrie P, Martin P, el Mestikawy S, Hamon M. 1987. Delayed behavioral response to antidepressant drugs following selective damage to the hippocampal noradrenergic innervation in rats. Brain Res 437:323-331.
49. Srebnik M, Ramachandran PV, Brown HC. 1988. Chiral synthesis via organoboranes, 18. Selective reductions. 43. Diisopinocam-pheylcholorborane as an excellent chiral reducing reagent for the synthesis of haloalcohols of high enantiomeric purity. A highly enantioselective nisoxetine. J Org Chem 53:2916-2920.
50. Storustovu S, Sanchez C, Porzgen P, Brennum LT, Larsen AK, Pulis M, Ebert B. 2004. R-citalopram functionally antagonizes escitalopram in vivo and in vivo: Evidence for kinetic interaction at the serotonin transporter. Br J Pharmacol 142:172-180.
51. Suarez-Roca H, Cubeddu LX. 2002. The selective serotonin reuptake inhibitor citalopram induces storage of serotonin in catecholaminergic terminals. J Pharmacol Exp Ther 302:174-179.
52. Tanda G, Carboni E, Frau R, Di Chiara G. 1994. Increase of extracellular dopamine in the prefrontal cortex: A trait of drugs with antidepressant potential? Psychopharmacology 115:285-298.
53. Thind KK, Boggan JE, Song T, Goldsmith PC. 1987. Immunostaining reveals accumulation of serotonin and coexistence with tyrosine hydroxylase in hypothalamic neurons of acutely stalked-sectioned baboons. Neuroendocrinology 45:130-145.
54. 2 dopamine receptor binding in humans measured with positron emission tomography. Psychopharmacology 126:277-280.
55. White FJ, Wang RY. 1983. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 225:1054-1057.
56. White FJ, Wang RY. 1984. Electrophysiological evidence for A10 dopamine autoreceptor subsensitivity following chronic d-amphetamine treatment. Brain Res 309:283-292.
57. Wong DT, Threlkeld PG, Robertson DW. 1991. Affinities of fluoxetine, its enantiomers, and other inhibitors of serotonin uptake for subtypes of serotonin receptors. Neuropsychopharmacology 5:43-47.
58. Zhou FM, Liang Y, Salas R, Zhang L, DiBiasi M, Dani JA. 2005. Co-release of dopamine and serotonin from striatal DA neurons. Neuron 46:65-74.